Surgery Partners, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Surgery Partners (SGRY) reported Q2 2026 revenue of $848.9M, up from $826.2M a year prior, but with a wider net loss of $15.0M. The company's M&A spending is below its $200M annual target due to disciplined acquisitions. Management expects revenue to reach $4.0B and earnings $72.9M by 2029, requiring 5.9% yearly revenue growth.
DeLuca Teresa purchased 10,000 shares of Surgery Partners, Inc. (SGRY) at $14.35 ($0.14M total) on 2026-08-18.
Surgery Partners (SGRY) reported Q2 2026 net revenue of about $849 million, up 2.7% year over year, and adjusted EBITDA of about $125 million, with a 14.7% margin. Same-facility net revenue rose 5%. For the first half, net revenue was about $1.66 billion (+3.6%) and adjusted EBITDA about $228 million. The company reaffirmed full-year guidance and said it will update forward guidance after a pending Idaho Falls transaction closes.
Over the past 7 days, alphai's AI scored 1 news story mentioning SGRY (Surgery Partners, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent SGRY coverage spans earnings, insider activity and sector analysis.
In the last 30 days, SGRY insiders filed 1 SEC Form 4 transaction — 1 purchase ($144K) and no sales. The most active reporter was DeLuca Teresa with 1 filing.
Slower M&A may pressure future EBITDA growth and increase risk to the investment thesis.
Insider buying may signal confidence in the company's outlook, potentially supporting the stock price.
Reaffirmed full-year guidance alongside same-facility revenue growth and margin pressure from payer mix shifts.
The article frames a positive earnings setup with reconfirmed guidance, but highlights margin pressure (operating margin down) and execution risks around divestiture, physician recruitment, and ASC growth.
Guidance disappointment is the key near-term risk signal for SGRY versus peers, likely keeping upside capped until management clarifies outlook drivers.
alphai scores every news story that mentions SGRY with an AI model for sentiment and relevance, and aggregates insider trades from Surgery Partners, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Surgery Partners (SGRY) reported Q2 2026 revenue of $848.9M, up from $826.2M a year prior, but with a wider net loss of $15.0M. The company's M&A spending is below its $200M annual target due to disciplined acquisitions. Management expects revenue to reach $4.0B and earnings $72.9M by 2029, requiring 5.9% yearly revenue growth.
2 min readDeLuca Teresa purchased 10,000 shares of Surgery Partners, Inc. (SGRY) at $14.35 ($0.14M total) on 2026-08-18.
1 min readSurgery Partners (SGRY) reported Q2 2026 net revenue of about $849 million, up 2.7% year over year, and adjusted EBITDA of about $125 million, with a 14.7% margin. Same-facility net revenue rose 5%. For the first half, net revenue was about $1.66 billion (+3.6%) and adjusted EBITDA about $228 million. The company reaffirmed full-year guidance and said it will update forward guidance after a pending Idaho Falls transaction closes.
8 min readSurgery Partners (SGRY) reported Q2 revenue of $848.9M versus $830.7M estimates and adjusted EPS of $0.10 versus $0.06, with adjusted EBITDA of $125.2M slightly above estimates. Management cited higher-acuity procedure growth and payer mix shift toward government reimbursement. Full-year revenue guidance was reconfirmed at $3.4B midpoint.
6 min readThe article highlights Q2 results for outpatient and specialty care firms. Surgery Partners (SGRY) reported slowest revenue growth and weaker full-year guidance, with the stock down 1.4% to $15.32. LifeStance (LFST) revenue rose to $435.4M (+26.1%) and shares rose 18.3% to $12.27. U.S. Physical Therapy (USPH) revenue $214.1M (+8.5%) and shares $81.96. Encompass Health (EHC) revenue $1.60B (+9.6%) and shares $124.69. agilon health (AGL) revenue $1.49B (+7.2%), shares $87.56.
6 min readSurgery Partners (NASDAQ:SGRY) reported Q2 same-facility revenue up 4.9% for the first half, driven by a 0.8% case increase and 4% net revenue per case. Management said commercial payer mix fell to about 49% of Q2 net revenue, with government payments rising. The company signed agreements to sell Idaho Falls assets for about $795M gross consideration and reaffirmed 2026 guidance excluding the deal.
6 min readSurgery Partners, Inc. (SGRY) reported Q2 results that exceeded expectations, citing revenue and adjusted EBITDA growth from higher acuity procedures and physician recruitment. The company said a pending Idaho Falls divestiture will simplify operations, reduce leverage, and focus on core short-stay surgical facilities. Full-year guidance was reaffirmed, with updated outlook after the sale closes.
1 min readSurgery Partners (NASDAQ:SGRY) shares fell 0.71% pre-market after Q2 results were mixed. Revenue rose to $848.9M, above the $830.05M forecast, and same-facility revenue grew 5%. Adjusted EPS was $0.10 vs $0.06 consensus, but GAAP net loss was $0.12/share. Adjusted EBITDA fell to $125.2M. Company reaffirmed 2026 revenue $3.35B-$3.45B and adjusted EBITDA at least $530M.
4 min readSurgery Partners (NASDAQ:SGRY) reported Q2 2026 revenue of $848.9M, above an $830.05M estimate, but posted an adjusted loss of $0.12 per share versus a $0.06 profit expectation. Same-facility revenue grew 5.0% on 4.8% rate growth. The company reaffirmed 2026 guidance: $3.35B to $3.45B revenue and at least $530M adjusted EBITDA, excluding the pending Idaho Falls divestiture.
6 min readSurgery Partners (NASDAQ: SGRY) reported Q2 CY2026 revenue of $848.9 million, up 2.7% year over year, beating Wall Street’s estimate by 2.2%. The company forecast full-year revenue around $3.4 billion. Non-GAAP EPS was $0.10, clearing consensus, and full-year EPS is expected to rise from $0.32 to $0.56.
6 min read
